Transforming Obesity Care: Insights from Experts on Semaglutide 2.4 mg
18 Sep 2025
With the launch of semaglutide 2.4 mg (Wegovy) in Singapore, a new chapter in the pharmacological treatment of obesity begins. MIMS Doctor spoke with two leading experts: Professor David Lau, an endocrinologist and Professor Emeritus of Medicine at the University of Calgary Cumming School of Medicine, Canada, and a key contributor to the 2020 Canadian Adult Obesity Guidelines, and Dr Georgia Rigas, Senior Bariatric Medical Practitioner at St George Private Hospital, Sydney, Australia, with extensive experience in primary care obesity management. Both experts shared compelling insights on how semaglutide 2.4 mg is set to transform obesity care across clinical settings.
Resources
Transforming Obesity Care: Insights from Experts on Semaglutide 2.4 mg
Transforming Obesity Care: Insights from Experts on Semaglutide 2.4 mg